Company / PP&E (Net)
ENDONOVO THERAPEUTICS, INC. PP&E (Net) History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.6K
FY2020
5-year range
$1.6K / $6.7K
FY2016-FY2020
Trend
-73.3%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 5 consecutive years, from $42,601 in FY2014 to $1,580 in FY2020.
Based on SEC 10-K filings.
$1,580 in FY2020 with a 5-year CAGR of -45.1%.
Declined from $6,727 to $1,580 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -45.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENDONOVO THERAPEUTICS, INC.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -45.1%, indicating a declining trend.
- In FY2020, pp&e (net) decreased 73.3% year-over-year.
- Peak pp&e (net) was recorded in FY2014.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $1.6K | -73.3% |
| FY2019 | $5.9K | -12.1% |
| FY2018 | $6.7K | -57.5% |
| FY2016 | $15.8K | -50.0% |
| FY2015 | $31.7K | -25.7% |
| FY2014 | $42.6K | +1867.7% |
| FY2011 | $2.2K | - |
As of FY2020 · SEC 10-K · Updated Jun 29, 2026